MultNAT® MTC Assay
Ongoing Challanges
- Despite medical advances, tuberculosis remains a global health crisis, with 10.6 million cases and 1.3 million deaths reported in 2022 (WHO)[1].
- Affected by the limitation of diagnostics, sputum smear microscopy misses ~50% of cases; culture takes 2–8 weeks. Molecular tests are costly and lack sensitivity for paucibacillary TB (children/HIV+ patients).
- 1.7 billion people harbor latent TB; 5–10% will develop active disease (higher if HIV+). 20–50% of patients skip doses due to stigma or treatment length.
REFERENCES:
[1] Global Tuberculosis Report 2022.
Product Overview
MultNAT® MTC Assay has been designed for the detection of Mycobacterium Tuberculosis Complex (MTC) based on the MultNAT® system.
- Simple process and integrated system with results within 80 minutes
- Designed to provide an accurate LOD: 30 CFU/ml
- Point-of-care (POC) Nucleic Acid Test Methodology to be applied in various medical scenarios
- Designed for the detection of accurate MTC with Nucleic Acid Amplification Test (NAAT) technology
Clinical Value
- Provides faster detection of TB and Rifampicin resistance, enabling timely treatment initiation.
- Early identification of TB allows for timely isolation and treatment, preventing the spread of the virus widespread .
- POC tests contribute real-time data for monitoring TB, aiding public health strategies.
Product Resources
MultNAT® MTC Assay
Brochure
MultNAT® MTC Assay
Instructions for Use
MultNAT® MTC Assay
SOP
